Alamar Biosciences Says Emory Study Using Its NULISA Platform Found Blood Protein Signature Identifying ALS With 98.3% Balanced Accuracy, Not A Clinical Test

Loading news article.

Alamar Biosciences Says Emory Study Using Its NULISA Platform Found Blood Protein Signature Identifying ALS With 98.3% Balanced Accuracy, Not A Clinical Test | WAPE

Alamar Biosciences Says Emory Study Using Its NULISA Platform Found Blood Protein Signature Identifying ALS With 98.3% Balanced Accuracy, Not A Clinical Test

Article summary

Related companies

Comments —